Drug intelligence / Profile preview

TPST-3000

Development stage: Preclinical
Lead developer: Tempest Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

TPST-3000 is an oral small molecule therapeutic being developed by Tempest Therapeutics. It is currently in IND-enabling studies for the treatment of relapsed/refractory multiple myeloma (rrMM) and systemic lupus erythematosus (SLE). While the specific biological target of TPST-3000 has not been publicly disclosed by the company, it is part of Tempest's pipeline of small molecules designed to modulate the immune system or directly target tumor cells. The program aims to address the significant unmet need in patients with advanced plasma cell dyscrasias and autoimmune conditions like lupus.

Beyond the preview

Go deeper on TPST-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPST-3000.

Explore the full profile